Emerging from the UK, retatrutide, a novel molecule, is sparking considerable excitement within the healthcare community regarding its promise for body control . This dual GIP and GLP-1 receptor agonist appears to deliver a significant advantage over existing therapies, showing positive results in preliminary clinical trials . Researchers think its